ECSP077739A - Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar - Google Patents

Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar

Info

Publication number
ECSP077739A
ECSP077739A EC2007007739A ECSP077739A ECSP077739A EC SP077739 A ECSP077739 A EC SP077739A EC 2007007739 A EC2007007739 A EC 2007007739A EC SP077739 A ECSP077739 A EC SP077739A EC SP077739 A ECSP077739 A EC SP077739A
Authority
EC
Ecuador
Prior art keywords
ezetimibe
cholesterol
sch
treatment
inhibitors
Prior art date
Application number
EC2007007739A
Other languages
English (en)
Inventor
Poblete Juan Francisco Miquel
Oddone Flavio Nervi
Rivera Atilio Gianpietro Gigotti
Matsuhiro Silvana Zanlungo
Original Assignee
Univ Pontificia Catolica Chile
Mimica Timosenko Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40329103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pontificia Catolica Chile, Mimica Timosenko Ivan filed Critical Univ Pontificia Catolica Chile
Publication of ECSP077739A publication Critical patent/ECSP077739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención demuestra que el uso de inhibidores específicos de la absorción intestinal de colesterol del tipo 2-AZETIDINONAS, específicamente EZETIMIBE (SCH 58235), inhibe completamente la formación de colelitiasis en un modelo murino de la enfermedad bajo dieta litogénica. Esta invención en un modelo preclínico de la enfermedad litiásica por cálculos de colesterol permite predecir que el bloqueo selectivo de la absorción intestinal de colesterol constituye una alternativa terapéutica eficaz en la prevención primaria y/o en el tratamiento de la colelitiasis en humanos. A su vez, como se argumentó en la sección del arte previo, es posible predecir que en humanos la combinación de ezetimibe (SCH 58235) más inhibidores de la neosíntesis hepática de colesterol (inhibidores de HMG-CoA reductasa), pudieran ser más eficaces que ezetimibe (SCH 58235) sólo para prevenir y/o tratar la litiasis vesicular.
EC2007007739A 2005-04-04 2007-09-14 Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar ECSP077739A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2005000762 2005-04-04

Publications (1)

Publication Number Publication Date
ECSP077739A true ECSP077739A (es) 2008-01-23

Family

ID=40329103

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007739A ECSP077739A (es) 2005-04-04 2007-09-14 Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar

Country Status (6)

Country Link
US (1) US8361999B2 (es)
EP (1) EP1865947A1 (es)
BR (1) BRPI0609614A2 (es)
EC (1) ECSP077739A (es)
MX (1) MX2007012253A (es)
WO (1) WO2006107936A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN110327449A (zh) * 2019-07-15 2019-10-15 王天罡 一种治疗胆结石的中药组合物及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
CN100439361C (zh) * 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ATE360630T1 (de) * 2003-12-19 2007-05-15 Bristol Myers Squibb Co Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors

Also Published As

Publication number Publication date
MX2007012253A (es) 2007-12-07
EP1865947A1 (en) 2007-12-19
BRPI0609614A2 (pt) 2010-04-20
US20100016273A1 (en) 2010-01-21
WO2006107936A1 (en) 2006-10-12
US8361999B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
ECSP077739A (es) Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
UY29633A1 (es) Derivados de oxindol
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
BRPI0515549A (pt) compostos, composições e métodos de inibição de toxicidade de alfa-sinucleìna
NO20076241L (no) Terapier for vaskulaere sykdommer
ECSP088117A (es) Agente desinfectante
EP1863899A4 (en) COMPOSITIONS FOR TREATING SKIN
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
NO20063368L (no) Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
EP1961494A4 (en) WASTE TREATMENT STRUCTURE OF A SPRAYER
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
EP1871462A4 (en) DC TISSUE TREATMENT
DK1933853T3 (da) Vævopbrydningsbehandling og sammensætning til brug derved